On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB:NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“Gamida Cell”), brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Under her leadership, Gamida Cell obtained United States Food and Drug Administration approval for Omisirge®, a groundbreaking stem cell therapy.
Related news for (NRXBF)
- NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
- NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
- NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award